T Cell News and Research

Latest T Cell News and Research

UCLA research sheds light on how brain tells time

The ability to tell time is fundamental to how humans interact with each other and the world. Timing plays an important role, for example, in our ability to recognize speech patterns and to create music. Patterns are an essential part of timing. The human brain easily learns patterns, allowing us to recognize familiar patterns of shapes, like faces, and timed patterns, like the rhythm of a song. But exactly how the brain keeps time and learns patterns remains a mystery.

21 Jun 2010

Study shows effective and efficient methods for producing recombinant proteins

A shift in the life science market has begun to steer cell culture scientists to re-evaluate their use of native transferrin and iron chelators to pursue recombinant alternatives. Transferrin regulates the uptake, transport and utilization of iron for cellular function, increasing cell growth and productivity. Native transferrin found in bovine or human serum has been widely used in cell culture for these added benefits. However, regulatory issues continue to arise with the use of native transferrin due to blood-borne pathogens.

21 Jun 2010

Exelixis announces regaining of rights to develop and commercialize XL184

Exelixis, Inc. today announced that it has regained full rights to develop and commercialize XL184. Exelixis and Bristol-Myers Squibb Company entered into a global development collaboration for XL184, the clinically most advanced MET inhibitor, in December 2008. Under the agreement, BMS and Exelixis had originally agreed to certain clinical development plans, and Exelixis maintained key rights regarding timing and funding of current and future clinical trials.

21 Jun 2010

Government's COE Program encourages research activities in universities across Japan: Study

Scopus- announced today that Kyoto University is employing the former's data and functions in a study performed by Dr. Takanori Ida, Professor at the Graduate School of Economics - Kyoto University. The study shows how effectively the government's large funding scheme, 21st Century Center of Excellence Program, encouraged research activities in universities across Japan.

21 Jun 2010

Prototype drug blocks MCL-1 protein that helps tumors survive treatment: Scientists

Scientists at Dana-Farber Cancer Institute have found a way to disable a common protein that often thwarts chemotherapy treatment of several major forms of cancer.

21 Jun 2010

New phase I/IIa clinical trial of AR-42 for blood cancer at OSUCCC-James

For the second time within a year, an experimental drug invented by cancer researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) is being tested on patients in a clinical trial.

19 Jun 2010

New insights into cancer hallmarks in induced pluripotent cells

The therapeutic potential of embryonic stem cells has been an intense focus of study and discussion in biomedical research and has resulted in technologies to produce human induced pluripotent stem cells (hiPSCs). Derived by epigenetic reprogramming of human fibroblasts, these hiPSCs are thought to be almost identical to human embryonic stem cells (hESCs) and provide great promise for patient-tailored regenerative medicine therapies.

19 Jun 2010

Oncolytics Biotech issued patent that covers methods for treating cell proliferative disorders

Oncolytics Biotech Inc. today announced that it has been granted its 35th U.S. Patent, # 7,731,951 entitled "Viruses for the Treatment of Cellular Proliferative Disorders." The patent claims cover methods for treating cell proliferative disorders by administering modified vaccinia virus to proliferating cells having an activated Ras-pathway.

19 Jun 2010

BioTime announces warrant discount offer

BioTime, Inc. announced today that it is commencing a warrant discount offer under which it will permit holders of its common share purchase warrants expiring October 31, 2010 to exercise their warrants at a discounted price of $1.818 per share, which represents a discount of $0.182 from the regular warrant exercise price of $2.00 per share.

19 Jun 2010

Preclinical study shows treatment with DAS181 inhibits infection with multiple HPIV strains

NexBio, Inc. announced today the publication of a "Major Article" in the Journal of Infectious Diseases of a preclinical study showing that treatment with DAS181 (Fludase) inhibits infection with multiple human parainfluenza virus strains. DAS181 is a broad spectrum host-targeted investigational drug candidate for treatment and prevention of Influenza-Like Illness.

19 Jun 2010

ThermoGenesis to seek stockholder approval for reverse stock split

ThermoGenesis Corp., a leading supplier of innovative products and services that process and store adult stem cells, said today it will seek stockholder approval of an authorization enabling its Board of Directors in its discretion to affect a reverse stock split in the range of one-for-three to one-for-five shares of common stock in the near future, if required to maintain NASDAQ listing. The authorization will be voted upon during a special meeting of stockholders to be held on Monday, August 9th.

19 Jun 2010

Ancient circadian clock regulates insulin production

The pancreas has its own molecular clock. Now, for the first time, a Northwestern University study has shown this ancient circadian clock regulates the production of insulin. If the clock is faulty, the result is diabetes.

19 Jun 2010

E'shee Clinical Esthetic introduces revolutionary new products for skin care

E'shee Skin Care products are the result of a careful collaboration of skin care professionals, doctors and chemists; these revolutionary new products are the next step in skin care.

19 Jun 2010

Cyclacel files Answer and Counterclaims to Celgene's declaratory judgment complaint

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that it filed its Answer and Counterclaims to the declaratory judgment complaint filed by Celgene Corporation.

18 Jun 2010

UCSB physicists create microscopic device to help biologists understand protein folding

Physicists at UC Santa Barbara have created a microscopic device to assist biologists in making very fast molecular measurements that aid the understanding of protein folding. This development may help elucidate biological processes associated with diseases such as Alzheimer's and Parkinson's. Since proteins in the body perform different functions according to their shape, the folding process is considered a key area of study.

18 Jun 2010

Gladstone Institute researcher to receive Kyoto Prize in Advanced Technology

The non-profit Inamori Foundation (President: Dr. Kazuo Inamori) today announced that Dr. Shinya Yamanaka will receive its 26th annual Kyoto Prize in Advanced Technology, which for 2010 focuses on the fields of Biotechnology and Medical Technology. Dr. Yamanaka, 47, will receive the award for his pioneering work in developing a technology to generate pluripotent stem cells that does not require the use of human embryos.

18 Jun 2010

Vitrolife acquires 25% participation in HertART Aps

Vitrolife has entered an agreement with the Danish company HertART Aps with regard to product development and distribution of IVF products and at the same time acquires a participation of 25 percent in the company.

18 Jun 2010

NeoStem announces presentation on very small embryonic-like stem cells at ISSCR 2010

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced today that a poster authored by NeoStem-affiliated scientists will be presented in a presentation at the premier stem cell research event, the International Society for Stem Cell Research (ISSCR) 8th Annual Meeting in San Francisco on June 17, 2010.

18 Jun 2010

Encouraging interim results from stem and regenerative cell-enriched fat grafting breast reconstruction trial

Interim results from a breast reconstruction trial show stem and regenerative cell-enriched fat grafting resulted in a high sustained rate of physician and patient satisfaction and persistent improvements in overall outcomes of the procedure at six and 12 months.

18 Jun 2010

Curis reports net income of $4.8M for first-quarter 2010: MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring Curis Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

18 Jun 2010

T Cell News and Research

Latest T Cell News and Research

UCLA research sheds light on how brain tells time

Study shows effective and efficient methods for producing recombinant proteins

Exelixis announces regaining of rights to develop and commercialize XL184

Government's COE Program encourages research activities in universities across Japan: Study

Prototype drug blocks MCL-1 protein that helps tumors survive treatment: Scientists

New phase I/IIa clinical trial of AR-42 for blood cancer at OSUCCC-James

New insights into cancer hallmarks in induced pluripotent cells

Oncolytics Biotech issued patent that covers methods for treating cell proliferative disorders

BioTime announces warrant discount offer

Preclinical study shows treatment with DAS181 inhibits infection with multiple HPIV strains

ThermoGenesis to seek stockholder approval for reverse stock split

Ancient circadian clock regulates insulin production

E'shee Clinical Esthetic introduces revolutionary new products for skin care

Cyclacel files Answer and Counterclaims to Celgene's declaratory judgment complaint

UCSB physicists create microscopic device to help biologists understand protein folding

Gladstone Institute researcher to receive Kyoto Prize in Advanced Technology

Vitrolife acquires 25% participation in HertART Aps

NeoStem announces presentation on very small embryonic-like stem cells at ISSCR 2010

Encouraging interim results from stem and regenerative cell-enriched fat grafting breast reconstruction trial

Curis reports net income of $4.8M for first-quarter 2010: MicroStockProfit.com

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in